(ASX:MSB) SINGLE INTERVENTION WITH REXLEMESTROCEL-L IMPROVES LEFT VENTRICULAR EJECTION FRACTION AT 12 MONTHS, PRECEDING LONG-TERM REDUCTION IN MAJOR ADVERSE CARDIOVASCULAR EVENTS
Key points:• Improvement in left ventricular ejection fraction (LVEF) at 12 months was shown after a singleintervention with rexlemestrocel-L in the 565-patient randomized controlled trial in New...
